Blair William & Co. IL Decreases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Blair William & Co. IL decreased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 9.5% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 44,477 shares of the biotechnology company’s stock after selling 4,685 shares during the quarter. Blair William & Co. IL’s holdings in Sarepta Therapeutics were worth $5,408,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Manchester Capital Management LLC boosted its position in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its stake in Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 156 shares in the last quarter. Sunbelt Securities Inc. boosted its holdings in shares of Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 232 shares during the last quarter. Newbridge Financial Services Group Inc. purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $36,000. Finally, Steward Partners Investment Advisory LLC increased its holdings in shares of Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 194 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the company’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the sale, the director now owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 7.70% of the company’s stock.

Analyst Ratings Changes

SRPT has been the topic of a number of recent research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $163.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Needham & Company LLC reissued a “buy” rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. HC Wainwright reaffirmed a “sell” rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday, March 19th. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a report on Wednesday, March 19th. Finally, Scotiabank cut their price target on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a report on Thursday, March 20th. One analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $167.41.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $70.41 on Monday. The company’s 50 day moving average is $102.66 and its two-hundred day moving average is $115.90. The firm has a market cap of $6.83 billion, a PE ratio of 56.33 and a beta of 0.79. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 52-week low of $68.78 and a 52-week high of $173.25.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.